Mann will not partner until it's approved, that way he can get a huge premium. He ain't no dummy!!!
Don't forget that this is still under $5 a share. When this creeps over (probably around May) you will see a lot of activity. The big boys will start moving around a lot. $6-$8 by Fall. This will not fall below $3.50 again.
I'm sure there will be a warning, but that will be normal. Look at some of the side effects for most drugs out there. If you read them all, you probably would never take them.
There is nothing else out there like this!!! This is the game changer. Not to mentions the Technosphere Technology-that's a multi-billion dollar business right there.
I don't think a "big pharma" drug company is going to enter into a partnership agreement with Mannkind prior to the next F.D.A. decision. The diminished lung capacity issue could results in a number of "REMS" requirements placed on Afrezza.
The liability issue could be a stumbling block. I think "thestreet" has similar expectations.
Diminished lung capacity is a non issue for normal patients. It was found to be "non clinical". The little bit there is was found to be completely reversible with discontinuation. The Street article talks about a study being done on patients with MOPD. This study will either expand the market, or lead to an exemption from use. It will have no bearing on the FDA's decision.